Annual report
2413.TEDINET S100R87E
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥169.2bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥131.0bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥113.1bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥72.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥95.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥58.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥34.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥30.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥37.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥21.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥19.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥52.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥66.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥400.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥346.0bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥273.1bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥221.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥137.3bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥91.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥82.0bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥309.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥264.0bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥207.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥302.6bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥257.8bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥199.8bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥166.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥98.7bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥118.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥104.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥89.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥27.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥46.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥26.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥17.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥3.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥49.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥11.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥43.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥5.0bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥55.73 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥31.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥30.22 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥55.68 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥31.88 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥30.2 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥293.64 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥244.24 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥151.97 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.2% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.9% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.9% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 20.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 21.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 10,533 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 8,249 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 7,127 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 6,024 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥49.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥26.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥27.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥30.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥27.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥28.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.2bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.9bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥232.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥215.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥195.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥163.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥97.8bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥70.6bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥62.9bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥162.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥152.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥139.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥122.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥65.8bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥87.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥92.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.41 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.03 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.67 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥32.38 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥18.02 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥13.66 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥205.3 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥180.54 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥101.23 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,785,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,645,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 647,957,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 588 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 554 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 473 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 421 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥4.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥4.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥3.2bn |
| Career Solutionreportable segment | employees | at 2023-03-31 | 673 pure |
| Career Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥14.5bn |
| Career Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥13.9bn |
| Career Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥669m |
| Career Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Evidence Solutionreportable segment | employees | at 2023-03-31 | 2258 pure |
| Evidence Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥27.2bn |
| Evidence Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥26.5bn |
| Evidence Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥630m |
| Evidence Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥7.7bn |
| Medical Platformreportable segment | employees | at 2023-03-31 | 2117 pure |
| Medical Platformreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥93.1bn |
| Medical Platformreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥90.2bn |
| Medical Platformreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2.9bn |
| Medical Platformreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥41.1bn |
| Overseasreportable segment | employees | at 2023-03-31 | 2283 pure |
| Overseasreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥62.1bn |
| Overseasreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥62.1bn |
| Overseasreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥25m |
| Overseasreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥17.0bn |
| Site Solutionreportable segment | employees | at 2023-03-31 | 2994 pure |
| Site Solutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥35.3bn |
| Site Solutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥35.0bn |
| Site Solutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥316m |
| Site Solutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥3.7bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥232.2bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥227.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥74.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥5.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥5.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥2.3bn |
| Career Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥14.1bn |
| Career Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.4bn |
| Career Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥740m |
| Career Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.6bn |
| Evidence Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥22.8bn |
| Evidence Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥21.9bn |
| Evidence Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥856m |
| Evidence Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.7bn |
| Medical Platformreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥85.9bn |
| Medical Platformreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥83.2bn |
| Medical Platformreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Medical Platformreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥39.6bn |
| Overseasreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥51.8bn |
| Overseasreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥51.8bn |
| Overseasreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥20m |
| Overseasreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥44.8bn |
| Site Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥35.2bn |
| Site Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.7bn |
| Site Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥525m |
| Site Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥209.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥204.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥98.1bn |
| Medical Platformreportable segment | employees | at 2023-03-31 | 511 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,649
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for acquisition of businesses inv cf IFRS | CurrentYearDuration | -2298000000 | JPY |
| Decrease due to loss of control over subsidiaries inv cf IFRS | Prior1YearDuration | -2986000000 | JPY |
| Decrease due to loss of control over subsidiaries inv cf IFRS | CurrentYearDuration | － | JPY |
| Other inv cf IFRS | Prior1YearDuration | 29000000 | JPY |
| Other inv cf IFRS | CurrentYearDuration | 522000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YearDuration | -23407000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYearDuration | -21933000000 | JPY |
| Dividends paid to owners of parent fin cf IFRS | Prior1YearDuration | -8144000000 | JPY |
| Dividends paid to owners of parent fin cf IFRS | CurrentYearDuration | -10860000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | Prior1YearDuration | -1591000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | CurrentYearDuration | -1790000000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YearDuration | － | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYearDuration | 140000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YearDuration | -3415000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYearDuration | -5730000000 | JPY |
| Repayments of borrowings fin cf IFRS IFRS | Prior1YearDuration | -13000000 | JPY |
| Repayments of borrowings fin cf IFRS IFRS | CurrentYearDuration | -809000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -3656000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -3902000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YearDuration | 126000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYearDuration | 90000000 | JPY |
| Other fin cf IFRS | Prior1YearDuration | 322000000 | JPY |
| Other fin cf IFRS | CurrentYearDuration | 24000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YearDuration | -16371000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYearDuration | -22837000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YearDuration | 2780000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYearDuration | 1723000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YearDuration | 15109000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYearDuration | 14066000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 89144000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 104253000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 104253000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 118319000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 83180000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 21899000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 13353000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 34660000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 51811000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 204903000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | 3256000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YearDuration | 208159000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000MedicalPlatformReportableSegmentMember | 2749000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000EvidenceSolutionReportableSegmentMember | 856000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000CareerSolutionReportableSegmentMember | 740000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000SiteSolutionReportableSegmentMember | 525000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000OverseasReportableSegmentMember | 20000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 4890000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05425-000OtherEmergingBusinessMember | 104000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -4994000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |